MBD: Standardisation of Investigations of Mild Bleeding Disorders
Study Details
Study Description
Brief Summary
Observational study aimed at evaluating the clinical impact of a standardised diagnostic procedure for the investigation of patients with suspected mild bleeding disorder (MBD).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The working hypothesis of this prospective diagnostic study is that a standardised procedure in investigating patients with suspected MBD will lead to a better discrimination between patients with and without MBD and a more precise characterisation of MBD.
The primary objective of this diagnostic study is to evaluate the efficiency of a standardised procedure of MBD in children and adults referred to their respective outpatient clinics for bleeding symptoms. The following endpoints will be evaluated:
-
The relative number of precise diagnosis (according to recognised classification of haemostatic disorders) in each clinical probability category;
-
The number of biological tests performed per patient in each clinical probability category;
-
The relative number of patients with no specialised investigations in the low risk group.
The secondary objective is to evaluate the bleeding events during a one-year follow-up. Follow-up will be performed with a phone call one year after the last consultation of the patient. The definition of a bleeding event will be any bleeding that promotes any specific medical attention (consultation, hospitalisation, transfusion, re-intervention in case of surgery). The detailed clinical history regarding each event will be collected. Bleeding events will be correlated to the clinical probability assessed at inclusion.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Possible MBD Defined by: a bleeding score >= 4 in adults; a bleeding score >= 2 in children (for girls, up to menses); a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is; a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score. In this group, the second step of investigations will be performed. |
Other: Second step of investigations
Second step according to results of the first step:
exploration of coagulation factors;
factor XIII and fibrinolysis investigations;
investigation of platelet function;
investigation of thrombocytopenia.
|
| MBD unlikely Patients without criteria for possible MBD as listed above. In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation. |
Other: Second step of investigations
Second step according to results of the first step:
exploration of coagulation factors;
factor XIII and fibrinolysis investigations;
investigation of platelet function;
investigation of thrombocytopenia.
|
Outcome Measures
Primary Outcome Measures
- Relative number of precise diagnosis [after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)]
Diagnosis are going to be evaluated according to recognized classification of haemostatic disorders
- Number of biological tests performed per patient [after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)]
- Relative number of patients with no specialised investigations in the low risk group [after the completion of the standardized diagnostic procedure (on average 1 week after enrollment in this low risk group)]
Secondary Outcome Measures
- Evaluation of bleeding events [After one year follow-up]
Phone call
Eligibility Criteria
Criteria
Inclusion Criteria:
- All patients aged more than two years-old referred by their physician (gynaecologist, paediatrician, general practitioner, surgeon, etc.) for investigations of a possible bleeding tendency will be included in this study. This prospective study will include consecutive patients attending the four outpatient clinics (Division of Angiology and Haemostasis and Paediatric Onco-Haematology Unit, University Hospitals of Geneva).
Exclusion Criteria:
- Pregnant women will be excluded because of modifications of the known modifications of the haemostasis system during pregnancy. Adult patients without discernment capacity will be excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Haemostasis unit, University Hospitals of Geneva | Geneva | Switzerland | 1205 |
Sponsors and Collaborators
- University Hospital, Geneva
Investigators
- Principal Investigator: Boehlen Francoise, MD, Haemostasis unit, University Hospitals of Geneva, Switerland
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10-246